Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity

Vaccine

Volumn 34, Issue 33, 2016, Pages 3882-3893

  Kowalczyk, Aleksandra ^a   Doener, Fatma ^a   Zanzinger, Kai ^a   Noth, Janine ^a   Baumhof, Patrick ^a   Fotin Mleczek, Mariola ^a   Heidenreich, Regina ^a  

^a CureVac GmbH   (Germany)

Author keywords

Antigen presenting cells; Boostability; Immunostimulation; Innate immunity; mRNA vaccine

Indexed keywords

MESSENGER RNA; RNA VACCINE; RNACTIVE; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOLOGICAL ADJUVANT; VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG SAFETY; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; IN VIVO STUDY; INJECTION SITE; INNATE IMMUNITY; LEUKOCYTE; LYMPH FLOW; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; FEMALE; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN-PRESENTING CELLS; CYTOKINES; FEMALE; IMMUNITY, INNATE; INJECTIONS, INTRADERMAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RNA, MESSENGER; VACCINES;

EID: 84977497384     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.05.046     Document Type: Article

References (37)

1. [1] Schlake, T., Thess, A., Fotin-Mleczek, M., Kallen, K.-J., Developing mRNA-vaccine technologies. RNA Biol 9 (2012), 1319–1330, 10.4161/rna.22269.
2. [2] Dubensky, T.W., Liu, M.A., Ulmer, J.B., Delivery systems for gene-based vaccines. Mol Med 6 (2000), 723–732.
3. [3] Platt, A., Wetzler, L., Innate immunity and vaccines. Curr Top Med Chem 13 (2013), 2597–2608.
4. [4] Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303 (2004), 1526–1529, 10.1126/science.1093620.
5. [5] Schlee, M., Master sensors of pathogenic RNA – RIG-I like receptors. Immunobiology 218 (2013), 1322–1335, 10.1016/j.imbio.2013.06.007.
6. [6] Brito, L.A., Chan, M., Shaw, C.A., Hekele, A., Carsillo, T., Schaefer, M., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. J. Am. Soc. Gene Ther. 22 (2014), 2118–2129, 10.1038/mt.2014.133.
7. [7] Thess, A., Grund, S., Mui, B.L., Hope, M.J., Baumhof, P., Fotin-Mleczek, M., et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther J Am Soc Gene Ther 23 (2015), 1456–1464, 10.1038/mt.2015.103.
8. [8] Fotin-Mleczek, M., Duchardt, K.M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother Hagerstown Md 2011:34 (1997), 1–15, 10.1097/CJI.0b013e3181f7dbe8.
9. [9] Van Lint, S., Goyvaerts, C., Maenhout, S., Goethals, L., Disy, A., Benteyn, D., et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 72 (2012), 1661–1671, 10.1158/0008-5472.CAN-11-2957.
10. [10] Sahin, U., Karikó, K., Türeci, Ö., MRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov 13 (2014), 759–780, 10.1038/nrd4278.
11. [11] Petsch, B., Schnee, M., Vogel, A.B., Lange, E., Hoffmann, B., Voss, D., et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 30 (2012), 1210–1216, 10.1038/nbt.2436.
12. [12] Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., Vom Dorp, F., et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer, 3, 2015, 26, 10.1186/s40425-015-0068-y.
13. [13] Weide, B., Carralot, J.-P., Reese, A., Scheel, B., Eigentler, T.K., Hoerr, I., et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother Hagerstown Md 2008:31 (1997), 180–188, 10.1097/CJI.0b013e31815ce501.
14. [14] Lorenz, C., Fotin-Mleczek, M., Roth, G., Becker, C., Dam, T.C., Verdurmen, W.P.R., et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 8 (2011), 627–636, 10.4161/rna.8.4.15394.
15. [15] Masopust, D., Ha, S.-J., Vezys, V., Ahmed, R., Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. J Immunol Baltimore Md 2006:177 (1950), 831–839.
16. [16] Elnekave, M., Bivas-Benita, M., Gillard, G.O., Sircar, P., Hovav, A.-H., A matter of timing: unsynchronized antigen expression and antigen presentation diminish secondary T cell responses. J Immunol Baltimore Md 2009:183 (1950), 1013–1021, 10.4049/jimmunol.0900283.
17. [17] Rees, W., Bender, J., Teague, T.K., Kedl, R.M., Crawford, F., Marrack, P., et al. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc Natl Acad Sci USA 96 (1999), 9781–9786.
18. + T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity 39 (2013), 496–507, 10.1016/j.immuni.2013.08.034.
19. [19] Sarén, P., Welgus, H.G., Kovanen, P.T., TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol Baltimore Md 1996:157 (1950), 4159–4165.
20. [20] Murphy, G., Gavrilovic, J., Proteolysis and cell migration: creating a path?. Curr Opin Cell Biol 11 (1999), 614–621.
21. [21] Flier, J., Boorsma, D.M., van Beek, P.J., Nieboer, C., Stoof, T.J., Willemze, R., et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 194 (2001), 398–405.
22. [22] Stanford, M.M., Issekutz, T.B., The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. J Leukoc Biol 74 (2003), 791–799, 10.1189/jlb.1102547.
23. [23] Calabro, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31 (2013), 3363–3369, 10.1016/j.vaccine.2013.05.007.
24. [24] Wilson, N.S., Yang, B., Morelli, A.B., Koernig, S., Yang, A., Loeser, S., et al. ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway. Immunol Cell Biol 90 (2012), 540–552, 10.1038/icb.2011.71.
25. [25] van Gisbergen, K.P.J.M., Sanchez-Hernandez, M., Geijtenbeek, T.B.H., van Kooyk, Y., Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J Exp Med 201 (2005), 1281–1292, 10.1084/jem.20041276.
26. [26] Duewell, P., Kisser, U., Heckelsmiller, K., Hoves, S., Stoitzner, P., Koernig, S., et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol Baltimore Md 2011:187 (1950), 55–63, 10.4049/jimmunol.1004114.
27. [27] Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C.M., Huber, C., et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70 (2010), 9031–9040, 10.1158/0008-5472.CAN-10-0699.
28. [28] Sebastian, M., Papachristofilou, A., Weiss, C., Früh, M., Cathomas, R., Hilbe, W., et al. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 14, 2014, 748, 10.1186/1471-2407-14-748.
29. [29] Kato, H., Sato, S., Yoneyama, M., Yamamoto, M., Uematsu, S., Matsui, K., et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23 (2005), 19–28, 10.1016/j.immuni.2005.04.010.
30. [30] Yoneyama, M., Kikuchi, M., Matsumoto, K., Imaizumi, T., Miyagishi, M., Taira, K., et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol Baltimore Md 2005:175 (1950), 2851–2858.
31. [31] Corr, M., von Damm, A., Lee, D.J., Tighe, H., In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol Baltimore Md 1999:163 (1950), 4721–4727.
32. [32] Janssen, E.M., Lemmens, E.E., Wolfe, T., Christen, U., von Herrath, M.G., Schoenberger, S.P., CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (2003), 852–856, 10.1038/nature01441.
33. [33] Ridge, J.P., Di Rosa, F., Matzinger, P., A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393 (1998), 474–478, 10.1038/30989.
34. [34] Han, S., Asoyan, A., Rabenstein, H., Nakano, N., Obst, R., Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc Natl Acad Sci USA 107 (2010), 20453–20458, 10.1073/pnas.1008437107.
35. [35] Richter, K., Brocker, T., Oxenius, A., Antigen amount dictates CD8+ T-cell exhaustion during chronic viral infection irrespective of the type of antigen presenting cell. Eur J Immunol 42 (2012), 2290–2304, 10.1002/eji.201142275.
36. [36] Hovav, A.-H., Panas, M.W., Rahman, S., Sircar, P., Gillard, G., Cayabyab, M.J., et al. Duration of antigen expression in vivo following DNA immunization modifies the magnitude, contraction, and secondary responses of CD8+ T lymphocytes. J Immunol Baltimore Md 2007:179 (1950), 6725–6733.
37. [37] Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum Vaccines Immunother 9 (2013), 2263–2276, 10.4161/hv.25181.